Migalastat Chaperone Therapy for Fabry Renal Impairment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Fabry disease, such as enzyme replacement therapy (ERT), struggle to effectively penetrate the kidneys and manage renal impairment, leading to progressive kidney damage and the need for dialysis or transplant, especially in patients with renal impairment.
Innovation Solution
Administering migalastat, a pharmacological chaperone, to Fabry patients with renal impairment at a frequency of once every other day, in doses ranging from 100 mg to 150 mg free base equivalent, to stabilize renal function, reduce plasma globotriaosylsphingosine, and enhance α-Gal A activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy (ERT) is administered to Fabry patients, then enzyme deficiency is addressed, but renal impairment cannot be effectively managed due to poor kidney penetration
Solution Approach 1:
The patent uses migalastat as a pharmacological chaperone that acts as an intermediary substance. It binds to mutant α-Gal A enzymes to stabilize their conformation and facilitate proper folding, enabling these enzymes to escape ER-associated degradation and reach the lysosome where they can function. This intermediary approach allows treatment of patients with specific mutant enzymes that would otherwise be degraded before reaching their functional destination.
Solution Approach 2:
The patent changes the physical-chemical parameters of the mutant enzyme by introducing migalastat binding. This stabilizes the enzyme's three-dimensional structure, increases its thermal stability, and prevents aggregation. The parameter change from unstable to stable conformation allows the enzyme to survive quality control mechanisms and reach functional locations, particularly in renal tissues where penetration is critical.
2Stability of the object's composition
If migalastat is administered at standard dosing frequency, then enzyme stability is improved, but treatment burden increases for patients with renal impairment
Solution Approach 1:
The patent implements a periodic dosing regimen of migalastat administered every other day (QOD) rather than daily. This periodic action maintains sufficient drug levels to stabilize mutant enzyme conformation while reducing the overall dosing burden on patients. The every-other-day schedule allows for drug accumulation and sustained enzyme stabilization without requiring daily administration, thereby improving ease of operation while maintaining therapeutic effectiveness.
3Reliability
If ERT is commenced early, then renal function may be preserved longer, but diagnosis is delayed due to disease rarity and misdiagnosis
Solution Approach 1:
The patent enables a form of self-service treatment where migalastat specifically targets and stabilizes the patient's own mutant enzyme variants. Unlike ERT which introduces external enzymes, migalastat works with the patient's endogenous mutant enzymes, enhancing their stability and function. This approach can be particularly valuable in cases of delayed diagnosis, as it activates the patient's existing enzymatic capacity rather than relying on external replacement, potentially preserving renal function even when treatment initiation is delayed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Migalastat therapy stabilizes renal function, reduces left ventricular mass index, and increases white blood cell α-Gal A activity, slowing the progression of renal impairment and improving enzyme activity in patients with mild to moderate renal impairment.
Implementation Method 1
A third approach to treating Fabry disease has been treatment with what are called pharmacological chaperones (PCs). Such PCs include small molecule inhibitors of α-Gal A, which can bind to the α-Gal A to increase the stability of both mutant enzyme and the corresponding wild type.
Data Source
Figure 1A
Figure 1B~1C
Figure 2
AI summary
Provided are methods for treatment of Fabry disease in a patient having renal impairment and/or elevated proteinuria. Certain methods comprise administering to the patient about 100 to about 150 mg free base equivalent of migalastat or salt thereof at a frequency of once every other day. Certain methods also provide for the stabilization of renal function, reducing left ventricular mass index, reducing plasma globotriaosylsphingosine and/or increasing α-galactosidase A activity in the patient.